Pharma News
22 Feb 2026 to 28 Feb 2026
Feb 28, 2026
Dr. Rajeev Singh Raghuvanshi has been reappointed as the Drugs Controller of India.
Dr. Rajeev Singh Raghuvanshi has been reappointed as Drugs Controller (India) at the Central Drugs Standard Control Organisation (CDSCO), as approved by the Appointments Committee of the Cabinet. This decision comes after a proposal from the Department of Health.
Feb 28, 2026
Establishing a Legal Obligation for Pharmaceutical Companies to Provide Services | Yale Law Journal
A recent note proposes treating patents for essential medicines, like insulin, as public franchises, imposing a duty to serve the public at reasonable prices. This approach aims to address the crisis of high prescription drug prices by ensuring equitable access and regulating manufacturers. The note draws on historical patent practices and common-law duties to advocate for reform in the pharmaceutical industry.
Feb 28, 2026
Examination of Competitive Landscape for Oral Small-Molecule GLP-1 Medications | Intellectia.AI
MDB Capital Holdings, LLC operates through three subsidiaries: MDB CG Management, Public Ventures, and PatentVest, focusing on broker-dealer services and intellectual property. Public Ventures specializes in securities offerings, while PatentVest provides patent research for investment banking. Additionally, MDB Minnesota One is developing a small molecule senescence platform, enhancing the company's technology development segment.
Feb 28, 2026
CollPlant Biotechnologies secures a patent in South Korea for its light-activated dermal filler technology.
CollPlant Biotechnologies has received a patent allowance from the Korean Patent Office for its photocurable dermal filler technology, which utilizes recombinant human collagen (rhCollagen). This innovation aims to enhance tissue augmentation and contour stability in aesthetic medicine. The patent extends through 2039, supporting CollPlant's strategy to enter the growing global injectable soft-tissue filler market, currently valued over $6 billion.
Feb 28, 2026
Section 101 Excludes Claims Related to Utilizing Biomarkers for Identifying Potential Drug-Induced Effects - JD Supra
The U.S. District Court ruled that Nextcea Inc.'s patent (U.S. Patent 8,313,949) for testing drug-induced phospholipidosis (DIP) was invalid, as it was deemed directed to natural phenomena without an inventive concept. The court emphasized that the claims merely observed correlations between biomarkers and lysosomal storage disorders, lacking specific treatment methods or innovative techniques.
Feb 28, 2026
Merck & Co. Inc.: Reasons This Major Pharmaceutical Stock Is Once Again Gaining Attention
Merck & Co. Inc. has recently generated significant attention due to its oncology pipeline and the performance of its cancer drug, Keytruda. As the company navigates patent expirations and regulatory pressures, it remains a key player in the healthcare sector, appealing to both long-term investors and short-term traders. The stock, traded under the ticker MRK, is under scrutiny for its potential volatility and future growth.
Feb 28, 2026
HIV has the potential to become resistant to the widely used antiviral lenacapavir, but this comes with a disadvantage for the virus.
A study published in Science Translational Medicine reveals that while HIV can develop resistance to lenacapavir, a groundbreaking long-acting antiviral drug, such mutations come with significant replication costs for the virus. Developed by Gilead Sciences, lenacapavir requires only two annual injections and targets the viral capsid, marking a significant advancement in HIV prevention and treatment.
Feb 28, 2026
Government Restructures CDSCO Zone Baddi in Response to Drug Quality Issues - Drugscontrol
The Centre has reorganized the Central Drugs Standard Control Organization (CDSCO) in Baddi to enhance oversight amid growing concerns over drug quality and regulatory issues. This move aims to address repeated red flags in one of India's largest pharmaceutical manufacturing hubs.
Feb 28, 2026
CDSCO launches SHRESTH index to enhance the efficiency of state drug regulatory agencies.
The Central Drugs Standard Control Organisation (CDSCO) has launched the State Health Regulatory Excellence (SHRESTH) Index to enhance the performance of state drug regulatory authorities. This initiative aims to promote collaboration and share successful practices among States and Union Territories (UTs).
Feb 28, 2026
TN, Karnataka, and Rajasthan report the largest number of NSQs in January - Drugscontrol
In January, Tamil Nadu, Karnataka, and Rajasthan reported the highest number of Not of Standard Quality (NSQ) drug samples, with Tamil Nadu accounting for approximately 29% of the total NSQ samples tested by state drug control authorities, according to data from the Central Drugs Standard Control Organization.
Feb 27, 2026
Keytruda: The Battle of Clones - Zerodha's Daily Update
Merck & Co.'s Keytruda, a leading cancer treatment, faces a patent expiration in 2028, prompting Indian pharmaceutical companies like Zydus Lifesciences and Dr. Reddy’s Laboratories to develop biosimilars. The complexity of recreating Keytruda, a biologic drug, poses significant challenges, but the potential market opportunity could lower treatment costs for cancer patients globally.
Feb 27, 2026
Seven pharmaceutical companies are targeting generic versions of semaglutide, with potential price reductions of 50% following the expiration of its patent, according to a report.
Prices of weight-loss drugs Wegovy and Ozempic, containing semaglutide, are set to drop in India after the patent expires on March 20, 2026. Indian companies like Sun Pharma, Zydus Lifesciences, and Dr Reddy’s Laboratories plan to launch affordable generics, potentially reducing costs by nearly 50%. This move is expected to significantly expand access to obesity treatments in the country.
Feb 27, 2026
Section 101 Excludes Claims Related to Utilizing Biomarkers for Identifying Potential Drug-Induced Effects...
The U.S. District Court ruled that Nextcea Inc.'s patent (U.S. Patent 8,313,949) for testing drug-induced phospholipidosis (DIP) was invalid, as it was deemed directed to natural phenomena without an inventive concept. The court emphasized that the claims merely observed correlations between biomarkers and lysosomal storage disorders, lacking specific treatment methods or innovative techniques.
Feb 27, 2026
India Set to Offer More Affordable Semaglutide Weight-Loss Medications; Physicians Caution Against Potential Misuse | Health
Experts warn against the unsupervised use of semaglutide for cosmetic weight loss, emphasizing it is not a quick fix and unsuitable for everyone. Dr. Rahul Jain highlights the risks of self-medication and stresses the importance of medical evaluation, understanding side effects, and lifestyle changes before starting the drug.
Feb 27, 2026
U.S. court dismisses Alvogen's attempt to contest Celgene's cancer medication patent - AOL
The U.S. patent office has rejected Alvogen Pine Brook LLC's challenge to Celgene Corp's patents on the myeloma drug Revlimid. This decision supports Bristol-Myers Squibb Co's $74 billion acquisition of Celgene, which aims to enhance its cancer drug portfolio. Revlimid generated $2.55 billion in revenue in Q4 2018 but may lose exclusivity in 2022.
Feb 27, 2026
Generate Biomedicines Raises $400 Million Through IPO to Fund Critical Trials for Severe Asthma Treatment
Generate Biomedicine has raised $400 million through its IPO, pricing 25 million shares at $16 each. The funds will support two pivotal clinical trials for its lead drug candidate, GB-0895, a TSLP-blocking antibody designed for six-month dosing in severe asthma. This innovative approach aims to improve patient adherence compared to existing biologics like Sanofi’s Dupixent and Amgen/AstraZeneca’s Tezspire.
Feb 27, 2026
Indian Pharmaceutical Companies Prepare to Introduce Generic Semaglutide Injections for Weight Management
Dr. Reddy's is set to launch a generic version of semaglutide, named Obeda, in March following the drug's patent expiry in India. Other pharmaceutical companies are expected to follow, potentially reducing prices of weight loss and diabetes injections by up to 50 percent, according to analysts.
Feb 27, 2026
Zydus plans to introduce a semaglutide injection featuring a reusable pen device on the day the patent expires.
Zydus Lifesciences is set to launch a generic semaglutide injection in India on the patent expiry day, approved for treating Type 2 diabetes and obesity. The innovative reusable pen device will deliver all dose strengths, aiming to enhance care standards. The drug will be marketed under the names Semaglyn, Mashema, and Alterme, with competition expected to lower prices significantly.
Feb 27, 2026
Xeris Biopharma's Subsidiaries Initiate Lawsuit for Patent Infringement on Recorlev® - Business Wire
Xeris Biopharma Holdings, Inc. has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics regarding Recorlev® (levoketoconazole) in the U.S. District Court for New Jersey. The lawsuit aims to prevent the sale of a generic version of Recorlev until Xeris's patents expire in March 2040. Xeris asserts confidence in its intellectual property rights.
Feb 26, 2026
Samchundang Obtains Exclusive Agreement for GLP-1 Medication Throughout Europe
Samchundang Pharmaceutical has signed an exclusive licensing agreement with a European pharmaceutical company for its oral GLP-1 generics, Rybelsus and Wegovy, in 11 European countries. The deal, valued at approximately 5.3 trillion KRW, allows Samchundang to capture a significant market share while utilizing its SNAC-free formulation technology. This strategic move positions the company for substantial growth in the diabetes and obesity treatment market.
Feb 26, 2026
The Complex Legal Dispute Involving Novo Nordisk and Hims & Hers - The Fashion Law
Novo Nordisk has filed a patent lawsuit against Hims & Hers over alleged infringement of its semaglutide patent, which is used in its drugs Ozempic, Wegovy, and Rybelsus. Hims' compounded semaglutide products are at the center of the dispute, which also includes a consumer class action questioning Hims' marketing claims. The outcomes could impact the GLP-1 treatment market significantly.
Feb 26, 2026
Supreme Court Requests Information on NAT Testing for Blood Safety Following Disturbing Events of ...
The Supreme Court of India has requested detailed information on the cost and availability of Nucleic Acid Amplification Testing (NAT) in government hospitals, emphasizing the need for safer blood transfusions amid rising incidents of transfusion mishaps. This move aims to reinforce the constitutional right to life under Article 21.
Feb 26, 2026
Numerous drug raids and confiscations of illegal substances in Haryana, Chhattisgarh, and Uttarakhand.
Law enforcement agencies in India have intensified operations against drug trafficking, resulting in multiple arrests and seizures of banned substances, including Tramadol, Alprazolam, and Codeine cough syrups, across Haryana, Chhattisgarh, Uttarakhand, Bihar, and Rajasthan. The surge in drug-related issues has prompted discussions in state assemblies for stricter controls under the NDPS Act.
Feb 26, 2026
Health: Jiuyuan Genetic in China aims to obtain approval for a biosimilar of Wegovy - Gdnonline
Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its experimental biosimilar Jikeqin, a version of Novo Nordisk's weight-loss drug Wegovy, in China. The application follows a Phase III trial showing Jikeqin's safety and efficacy. Jiuyuan is also pursuing approval for a biosimilar of Ozempic, as patents for both drugs are set to expire in March.
Feb 26, 2026
PatentVest Publishes Pulse Report on Oral Small-Molecule GLP-1 Initiatives and ...
PatentVest's latest report, "The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron," analyzes the competitive landscape of oral GLP-1 drugs, revealing over 1,200 patent documents from 26 programs. With the injectable GLP-1 market valued at $71 billion, the report emphasizes the importance of patent strength for market dominance as key patents for drugs like semaglutide and tirzepatide approach expiration.
Feb 26, 2026
PatentVest Publishes Latest Report on the Competition for Oral Small-Molecule GLP-1 Patents
PatentVest has released a report analyzing the competitive landscape of oral small-molecule GLP-1 drugs, highlighting over 50 programs vying for market share as injectable GLP-1 drugs reach a $71 billion market. The report emphasizes the importance of patent strength for long-term success, with key players including Eli Lilly, Novo Nordisk, and Pfizer.
Feb 26, 2026
The potential impact of machine learning on the pharmaceutical sector - Felix
Professor Miraz Rahman discusses the transformative potential of machine learning (ML) in drug discovery and development, emphasizing its role in optimizing clinical trials and formulation processes. Despite the promise, he notes that ML is still in its early stages and requires high-quality data and collaboration between sectors to unlock its full potential.
Feb 26, 2026
Xeris Biopharma's Subsidiaries Initiate Lawsuit for Patent Infringement on Recorlev® - Yahoo Finance
Xeris Biopharma Holdings, Inc. has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over their attempts to produce a generic version of Recorlev® (levoketoconazole). The lawsuit aims to protect four patents set to expire in March 2040. Xeris CEO John P. Shannon expressed confidence in their intellectual property rights.
Feb 26, 2026
Impending Medication Shortage Poses Risks to Worldwide Healthcare Systems | Streamline Feed
A report highlights a looming crisis in pharmaceutical development as the rollout of affordable biosimilars struggles to keep pace with expiring patents of key drugs like Merck's Keytruda and Bristol Myers Squibb's Opdivo. Delays in introducing cheaper alternatives threaten global healthcare, particularly in developing nations like Kenya, where access to life-saving medications remains a critical issue.
Feb 26, 2026
Novo Nordisk Plans to Reduce Wegovy's US List Price by 50% Starting in 2027 - NTD
Novo Nordisk announced it will reduce the U.S. list prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% starting January 1, 2024, bringing the monthly cost to $675. This move aims to benefit consumers linked to list prices, coinciding with new Medicare pricing. The price cuts reflect increasing competition in the GLP-1 drug market.
Feb 26, 2026
Hanmi takes on Wegovy; Samsung speeds up its AI drug development efforts - KED Global
South Korean anti-obesity drugmakers are intensifying competition in the global weight management market, spurred by the success of the blockbuster medication Wegovy. Companies like Hanmi Pharmaceutical are exploring innovative drug delivery technologies to capture niche demand in this evolving landscape.
Feb 26, 2026
Why SCHOTT Pharma Has Captured the Attention of Biotech Investors - Ad-hoc-news.de
SCHOTT Pharma is gaining attention as a key player in the injectable drug market, supplying essential packaging like glass syringes and vials for GLP-1 weight-loss drugs, vaccines, and biologics. With rising demand in the US, the company is seen as a stable investment amid healthcare trends, attracting interest from institutional investors. Its stock is listed as Schott Pharma Aktie in Germany.
Feb 26, 2026
Jiuyuan Genetic from China is pursuing authorization for a biosimilar of Wegovy. | WTVB
Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar Jikeqin, a version of Novo Nordisk's weight-loss drug Wegovy, in China. The application follows a Phase III trial showing Jikeqin's safety and efficacy. Jiuyuan is also pursuing approval for a biosimilar of Ozempic, as patents for both drugs are set to expire soon.
Feb 26, 2026
Major metabolic breakthroughs make their way into the bloodstream - Medical Republic
A Lancet Haematology editorial emphasizes the urgent need for research on GLP-1 receptor agonists (GLP-1RAs) due to emerging evidence linking these diabetes drugs to malignancy and thrombosis. Observational studies suggest GLP-1RAs may lower risks of myelodysplastic syndromes and thromboembolic events, highlighting the necessity for further investigation into their mechanisms and potential benefits in haematological conditions.
Feb 26, 2026
Medical Insights: Exploring the Development of the "Leading Weight-Loss Medication" - 36氪
Eli Lilly's Tirzepatide has become the new global drug sales champion in 2025, achieving $36.507 billion in sales, surpassing Novo Nordisk's Semaglutide, which reached $36.1 billion. Both drugs, part of the GLP-1 receptor agonist family, are pivotal in treating type 2 diabetes and obesity, marking a significant shift in the pharmaceutical landscape.
Feb 26, 2026
Sales at Chemist Warehouse surge due to weight-loss medications - AFR
Chemist Warehouse reports strong double-digit sales growth driven by rising demand for blockbuster weight-loss drugs. The company anticipates further acceleration if cheaper pill versions of weekly injections enter the Australian market this year. Following this news, shares in Sigma Healthcare, which merged with Chemist Warehouse, rose 2.3% to $3.06.
Feb 26, 2026
Cost of Weight-Loss Medications in India Expected to Decrease as Semaglutide Patents Lapse - NDTV
India's anti-obesity drug market is set for a transformation as the patent for semaglutide, used in popular drugs like Ozempic and Wegovy, expires on March 20, 2026. Generic versions from companies like Sun Pharma and Dr. Reddy's are expected to halve prices, enhancing access to weight-loss treatments for patients with obesity and diabetes.
Feb 26, 2026
Sam Chun Dang secures a deal across 11 European nations for oral semaglutide generics, offering a 60% profit share.
Sam Chun Dang Pharm has secured exclusive commercialization rights for generic oral semaglutide in 11 European countries, including the UK and Sweden, through a licensing agreement. The deal, valued at €30 million upfront, allows the company to profit share 60% from sales of generics of Novo Nordisk’s Rybelsus and Wegovy. Sam Chun Dang aims to bypass certain patents with a new formulation.
Feb 25, 2026
Genprex Obtains Important International Patents for REQORSA Treatment - The Globe and Mail
Genprex (GNPX) announced that the Japanese Patent Office granted a patent for REQORSA Gene Therapy combined with PD-L1 antibodies, while the European Patent Office granted a similar patent for its use with PD-1 antibodies. These patents support the Acclaim-3 trial for small cell lung cancer, evaluating REQORSA with Genentech’s Tecentriq. The company aims to strengthen its global intellectual property portfolio.
Feb 25, 2026
Korean biosimilars prepare for a surge of major patent expirations
The global pharmaceutical market faces a significant patent cliff, with around 200 drugs, including blockbuster medications like MSD's Keytruda and Bristol Myers Squibb's Opdivo, losing exclusivity by 2030. Korean companies, notably Celltrion and Samsung Bioepis, are racing to develop biosimilars to capitalize on these opportunities, conducting clinical trials for drugs like CT-P51 and SB27 to secure market share.
Feb 25, 2026
Envoy Medical secures three additional patents to enhance its standing in the cochlear implant industry.
Envoy Medical Inc. has announced the issuance of three new patents, enhancing its intellectual property in the cochlear implant industry. The patents include US patent No. 12,544,564 for improved signal processing and two Hong Kong patents for a combination hearing aid and cochlear implant system. The Acclaim cochlear implant, currently in clinical trials, received FDA Breakthrough Device Designation in 2019.
Feb 25, 2026
Reasons behind the impending 50% price reduction of 'miracle' weight loss medications in India.
India's anti-obesity market is set for a major shift as several pharmaceutical companies plan to introduce more affordable versions of popular weight-loss drugs like Wegovy and Ozempic. This move is expected to broaden access to obesity treatment, which has primarily been available to affluent urban patients due to high costs and long-term usage requirements.
Feb 25, 2026
Novo secures opportunity for improved oral obesity medications through Vivtex agreement | BioPharma Dive
Novo Nordisk has partnered with startup Vivtex to develop new oral biologics for obesity and metabolic diseases, potentially worth up to $2.1 billion. This collaboration aims to leverage Vivtex's innovative drug screening technology, enhancing patient access to oral medications. Novo's previous successes include the oral biologic Rybelsus and an upcoming oral version of Wegovy.
Feb 25, 2026
Four charts illustrate the extent of Novo Nordisk's challenges - CNBC
Novo Nordisk, once a leader in GLP-1 weight loss drugs, faces significant challenges as its stock plummets 75% since mid-2024. Competition from Eli Lilly, pricing pressures, and disappointing trial results for its drug CagriSema have eroded its market share. CEO Mike Doustdar warns of declining sales and profits in 2026, marking a potential first annual drop since 2017.
Feb 25, 2026
Sources indicate that Indian pharmaceutical company Dr. Reddy's is preparing for the launch of its generic semaglutide, Obeda, in March.
Dr. Reddy’s Laboratories is set to launch its generic semaglutide injection, branded as Obeda, in India by March. The drug, a competitor to Novo Nordisk’s Ozempic and Wegovy, will be priced up to 60% lower than the branded versions. With rising diabetes and obesity rates in India, Dr. Reddy’s aims to sell 12 million pens in the first year.
Feb 25, 2026
Formycon AG / DE000A1EWVY8 - Press Release from Ad-hoc-news.de
Formycon AG announced successful results from the Dahlia pharmacokinetic study, demonstrating bioequivalence of its biosimilar FYB206 (pembrolizumab) with Keytruda®. This milestone strengthens Formycon's position in biosimilar development, as they prepare for regulatory approval. Keytruda®, a leading cancer treatment, generated $31.7 billion in sales in 2025. Formycon aims to enhance patient access to this essential therapy.
Feb 25, 2026
Formycon reveals encouraging clinical results for its Keytruda® biosimilar candidate, FYB206.
Formycon AG announced positive clinical results for its Keytruda® biosimilar candidate FYB206 (pembrolizumab), demonstrating pharmacokinetic equivalence in the pivotal Dahlia study. The company aims to finalize regulatory documents and expedite FYB206's availability post-Keytruda® exclusivity. This milestone reinforces Formycon's position as a leading biosimilar developer in oncology.
Feb 25, 2026
Novo Nordisk plans to reduce the US list price of Wegovy by 50% starting in 2027 - ET Pharma
Novo Nordisk announced a significant price reduction for its diabetes and weight-loss drugs, Ozempic and Wegovy, cutting U.S. list prices by up to 50% to $675 per month, effective January 1. This move aligns with new Medicare pricing and aims to alleviate costs for insured patients. The price cuts reflect increasing competition in the GLP-1 drug market.
Feb 25, 2026
2026 Market Analysis for Large Molecule Drug Substance CDMO: Size, Share, Trends, and Growth Insights
The large molecule drug substance CDMO market is expected to grow at a CAGR of 9%, driven by rising demand for biologics and biosimilars, advancements in bioprocessing, and increased FDA and EMA approvals. Key players include Eurofins Scientific, WuXi Biologics, and Boehringer Ingelheim. The shift towards biologics is reshaping the pharmaceutical landscape, enhancing treatment options for chronic diseases.
Feb 25, 2026
The Influence of Clinical Trials on Innovation and Inventiveness in Pharmaceutical Patents - Mondaq
Clinical trials play a crucial role in determining the safety and efficacy of medicinal products, impacting patentability under both European and Turkish law. The confidentiality of trial data can preserve novelty, as seen in recent court decisions regarding zoledronic acid. Effective confidentiality measures and strategic patent application timing are essential for pharmaceutical companies to protect their innovations.
Feb 25, 2026
Semaglutide Patent Expiration: Indian Pharmaceutical Industry Braces for Price Competition - Whalesbook
The March 2026 patent expiry for semaglutide, a key ingredient in weight-loss drugs, is set to ignite a price war among Indian pharma firms like Sun Pharma, Dr. Reddy's, and Zydus Lifesciences, with day-one generic launches expected. This could reduce prices by 75% and double the market size, significantly impacting innovator brands and intensifying competition.
Feb 25, 2026
Exploring the Convergence of Biotechnology, Intellectual Property Law, and Artificial Intelligence with Dr. Kate Neville, IP Lawyer
Kate Neville of Marshall Gerstein discussed the importance of intellectual property in the life sciences on the BioTalk Unzipped podcast. She emphasized the role of patent strategy in commercial success and the impact of AI tools on patent processes. The conversation also addressed women in biotech leadership and venture funding disparities.
Feb 25, 2026
Delhi High Court ruling allows for the cancellation of expired patents, providing a boost for generic drugs.
A recent court ruling clarified that patent owners can pursue damages from generic drugmakers for infringement during the patent's validity. However, if a patent is challenged and later revoked post-expiry, any damages claims will be nullified, treating the patent as if it never existed.
Feb 24, 2026
Major pharmaceuticals are set to encounter a significant patent expiration wave in 2026 | Drug Discovery News
The pharmaceutical industry faces a significant patent cliff in 2026, with major drugs like Merck's Januvia and Janumet, and Pfizer's Xeljanz set to lose exclusivity. This shift could lead to over $230 billion in lost revenue as generics enter the market. Companies like Bristol Myers Squibb also face challenges with Eliquis, highlighting the need for strategic adaptation.
Feb 24, 2026
Novo Nordisk plans to reduce the prices of GLP-1 medications beginning in 2027 - Sherwood News
Novo Nordisk announced it will reduce the list prices of its GLP-1 drugs, including the weight-loss drug Wegovy by up to 50% and diabetes drug Ozempic by 35%, starting next year. This decision aims to improve access for patients facing high out-of-pocket costs, amid increasing competition from Eli Lilly's more effective offerings.
Feb 24, 2026
Novo plans to reduce prices for Ozempic and Wegovy in response to growing competition.
Novo Nordisk will reduce the list prices of its weight-loss drugs Ozempic, Rybelsus, and Wegovy to $675 per month starting January 1, 2027, down from over $1,000. This move aims to improve affordability for insured consumers. The announcement follows disappointing results for its new drug CagriSema compared to Eli Lilly's Zepbound, which has gained market share.
Feb 24, 2026
Merck & Co plans to establish an independent cancer division in light of impending patent expirations - The Economic Times
Merck & Co is restructuring its drug division into two separate businesses to highlight its fastest-growing medicines, particularly as the cancer therapy Keytruda approaches patent expiration. The company aims to focus on newer products, including a pneumonia vaccine and a lung disease treatment, as pivotal drivers for its next growth phase.
Feb 24, 2026
Novo Nordisk plans to reduce the US list price of Wegovy by 50% starting in 2027 - WHTC
Novo Nordisk announced it will reduce the U.S. list prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% starting January 1, 2024, bringing the price to $675 a month. This move aims to benefit consumers linked to list prices, amid increasing competition in the GLP-1 drug market.
Feb 24, 2026
Novo Nordisk plans to reduce the US list prices of Wegovy and Ozempic starting in 2027 - Capital Brief
Danish drugmaker Novo Nordisk announced it will reduce the US list prices of its weight loss drugs, including Wegovy and Ozempic, by up to 50% starting January 1, 2027. The new monthly price will be USD675, aiming to increase market share and improve access for over 100 million Americans with obesity and 35 million with type 2 diabetes.
Feb 24, 2026
Novo plans to reduce prices for Ozempic and Wegovy in response to growing competition - The Detroit News
Novo Nordisk will reduce the list prices of its diabetes and weight-loss drugs Ozempic, Rybelsus, and Wegovy to $675 per month starting January 1, 2027, down from over $1,000. This move aims to enhance affordability for insured consumers. The price cuts come amid competition from Eli Lilly's Zepbound and following disappointing results for Novo's CagriSema in weight-loss trials.
Feb 24, 2026
Widespread price competition leads to lower costs for popular weight-loss medications - Deseret News
Novo Nordisk plans to cut prices for its weight-loss drug Wegovy by 35% and diabetes drug Ozempic by 50%, effective January 1, 2027. The new monthly cost will be $675 for insured patients. This move aims to enhance affordability amid intense competition in the GLP-1 drug market, where rivals like Eli Lilly are also reducing prices.
Feb 24, 2026
Novo Nordisk plans to reduce the US list price of Wegovy by 50% starting in 2027 - WTAQ
Novo Nordisk announced it will reduce the U.S. list prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% starting January 1, 2024, bringing the price to $675 a month. This move aims to benefit consumers linked to list prices, amid increasing competition in the GLP-1 drug market.
Feb 24, 2026
Well-known weight-loss medications are becoming more affordable due to a competitive pricing battle - Yahoo Finance
Novo Nordisk plans to reduce the list prices of its GLP-1 drugs, including Wegovy, Ozempic, and Rybelsus, to $675 a month starting January 1, 2027. This represents a 50% cut for Ozempic and 35% for Wegovy, aimed at improving affordability for insured patients. The move comes amid intense competition in the weight-loss drug market.
Feb 24, 2026
Prices for Ozempic and Wegovy are set to decrease by 50% by 2027 | 104.7 KISS FM Phoenix
Novo Nordisk will reduce the U.S. list prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%, effective January 1, 2027. The new monthly price will be $675, down from $1,349 for Wegovy and $1,028 for Ozempic. This move aims to enhance affordability for patients amid increasing competition from Eli Lilly's Zepbound and Mounjaro.
Feb 24, 2026
Novo Nordisk plans to reduce the US list price of Wegovy by 50% starting in 2027.
Novo Nordisk announced a significant price reduction for its diabetes and weight-loss drugs, Ozempic and Wegovy, cutting U.S. list prices by up to 50% to $675 per month, effective January 1. This move coincides with new Medicare pricing and aims to alleviate costs for insured patients. The price cuts also apply to Rybelsus, amid increasing competition in the GLP-1 drug market.
Feb 24, 2026
Eli Lilly Declines Following Price Reductions by Novo Nordisk - TradingView
Eli Lilly and Company (LLY) shares fell in premarket trading following Novo Nordisk A/S's announcement to cut U.S. list prices for its GLP-1 drugs, including Wegovy and Ozempic, by 35% to 50% starting in 2027. This pricing strategy aims to enhance affordability, intensifying competition in the obesity and diabetes treatment market, where Lilly's Zepbound and Mounjaro are also competing.
Feb 24, 2026
Weight-loss medications expected to see price reductions - The Times of India
The Indian anti-obesity market is set for a transformation as several pharma companies, including Sun Pharma, Zydus Lifesciences, and Dr Reddy's, prepare to launch affordable versions of semaglutide-based drugs Wegovy and Ozempic following the patent expiry. Analysts predict a significant price drop, potentially making generics 50% cheaper, and expect the market to double in a year.
Feb 24, 2026
Exploring the Conflict Surrounding Elevated Prescription Drug Prices in the United States | FRONTLINE - PBS
The Trump administration has launched TrumpRx, a website aimed at helping U.S. consumers purchase affordable prescription drugs. This initiative highlights ongoing concerns over high drug prices, as explored in the 2003 documentary "The Other Drug War." The film examined the struggles of seniors seeking cheaper medications and the debate over government price controls, which remain contentious today.
Feb 24, 2026
Apotex is set to launch a $1 billion IPO - The Globe and Mail
Apotex Inc., Canada’s largest pharmaceutical company, plans to go public with a share sale worth up to $1 billion, following its acquisition by SK Capital Partners LP in 2023. The IPO aims to highlight Apotex's commitment to affordable medicine and will be led by CEO Allan Oberman, a former Teva executive. This would mark the largest IPO on the Toronto Stock Exchange since 2021.
Feb 24, 2026
Foreign direct investment in the pharmaceutical sector has not led to technology transfers, and policymakers should maintain their current stance.
Novartis AG's exit from its Indian subsidiary highlights a trend of multinational drug companies reducing operations in India, focusing instead on high-value imports. Despite India's adoption of product patents in 2005, stringent regulations hinder foreign investment and R&D. Policymakers are urged to maintain current patent policies to support domestic growth and innovation in the pharmaceutical sector.
Feb 24, 2026
BioRestorative Therapies Secures Patent for Groundbreaking Brown Adipose-Derived Technology...
BioRestorative Therapies, Inc. announced the allowance of a patent for its ThermoStem® technology, aimed at treating obesity and metabolic disorders using brown adipose-derived stem cells. This development positions BioRestorative as a potential alternative to GLP-1 drugs, which face tolerability and safety concerns. CEO Lance Alstodt emphasized the importance of expanding their global patent protection in this competitive field.
Feb 24, 2026
Understanding the Delhi High Court's Decision: The Connection Between Injunctive Relief and Patents...
The Delhi High Court ruled in favor of Dr. Reddy’s Laboratories in a patent dispute with Novo Nordisk over Semaglutide, a diabetes and obesity drug. The court allowed Dr. Reddy’s to manufacture and export the drug to non-patent jurisdictions but prohibited sales in India, citing a credible challenge to the patent's validity. The ruling emphasizes the balance between patent rights and competition.
Feb 24, 2026
BioRestorative Enhances Worldwide Safeguards for ThermoStem®, a Promising Long-Term Solution...
BioRestorative Therapies, Inc. has received patent approval in Australia for its ThermoStem® technology, which utilizes brown adipose-derived stem cells to potentially treat obesity and metabolic disorders. This development aims to provide safer, longer-lasting alternatives to GLP-1 drugs, which have limitations such as tolerability issues and cardiovascular risks. CEO Lance Alstodt emphasized the company's commitment to advancing cell-based therapies.
Feb 24, 2026
A Comprehensive Guide to Biosimilars and Patents in the UK - Mondaq
The European Medicines Agency (EMA) defines biosimilars as biological medicines highly similar to approved reference medicines. Developers must demonstrate comparability through studies, benefiting from prior clinical trials. Initiatives like the Bolar Exemption and SPC manufacturing waivers aim to enhance market access for biosimilars, promoting competition and affordability while balancing innovators' IP rights.
Feb 24, 2026
Merck plans to establish a distinct division for cancer treatment in anticipation of the impending patent expiration for Keytruda - ET Pharma
Merck announced the creation of a separate division for its cancer business, centered around its leading drug Keytruda, ahead of its patent expiry in 2028. This restructuring aims to enhance pipeline success and may allow for future spin-offs. Keytruda, the world's best-selling prescription medicine, generated over $30 billion in 2025, constituting nearly half of Merck's revenue.
Feb 24, 2026
Merck's Keytruda Expected to Maintain Its Leading Position for Several More Years, Potentially Worth Billions
Merck's Keytruda, a leading cancer drug, may enjoy extended exclusivity beyond the expected 2028 patent expiration, potentially generating an additional $22 billion in sales through 2033, according to Bloomberg Intelligence. The analysis highlights Merck's robust patent portfolio and the recent approval of Keytruda Qlex, which could further delay revenue erosion amid upcoming biosimilar competition.
Feb 23, 2026
Johnson & Johnson and AbbVie: A Competitive Growth Battle in the Face of Patent Expirations
Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent players in the pharmaceutical sector, focusing on immunology, oncology, and neuroscience. JNJ's growth is driven by drugs like Stelara and Darzalex, while ABBV relies on Humira, Skyrizi, and Rinvoq. Both face patent challenges but show strong sales growth, with JNJ's stock rising 48.1% and ABBV's by 10.2% over the past year.
Feb 23, 2026
Novo Nordisk Declines While Lilly Rises Following Surprising Results from Obesity Medication Trial - TradingView
Novo Nordisk's shares dropped over 12% after its late-stage trial for CagriSema, a combination of cagrilintide and semaglutide, showed weaker weight loss results compared to Eli Lilly's tirzepatide. CagriSema achieved a 20.2% weight loss after 84 weeks, falling short of the 23.6% seen with tirzepatide, raising concerns about its market competitiveness.
Feb 23, 2026
Eli Lilly introduces monthly multidose Zepbound pens through LillyDirect - TechTarget
Eli Lilly has launched the KwikPen, a multi-dose option for its obesity drug Zepbound, following FDA approval for label expansion. The device allows patients to administer a month's worth of doses in one injection. Priced at $299 for the lowest dose, it aims to enhance convenience in obesity treatment. Zepbound is also available in single-dose formats.
Feb 23, 2026
Eli Lilly introduces the Zepbound pen, providing a month's supply of doses - Redmayne Bentley
Eli Lilly & Co has launched a new multi-dose Zepbound pen, providing a month's worth of doses for obesity treatment. The announcement boosted shares by 3.6%. Zepbound, which contains tirzepatide, outperformed Novo Nordisk's CagriSema in clinical trials, achieving 25.5% weight loss compared to CagriSema's 23%. The KwikPen aims to enhance patient choice in obesity management.
Feb 23, 2026
Novo Nordisk Shares Drop 15% Following 'CargiSema' Underperformance Compared to Eli Lilly's Weight Loss Medication
Novo Nordisk's stock fell 15% after its weight loss drug, CargiSema, failed to demonstrate non-inferiority to Eli Lilly's Tirzepatide in trials. CargiSema achieved a 23% weight loss compared to Tirzepatide's 25.5%. Eli Lilly's stock rose 3.5% following the news. Novo plans further trials to explore CargiSema's potential.
Feb 23, 2026
Eli Lilly introduces the Zepbound pen, providing a month's supply of doses - Sharecast.com
Eli Lilly & Co launched a new multi-dose KwikPen for its obesity drug Zepbound, allowing a month's worth of doses in one device. Shares rose 3.6% following news that Novo Nordisk's CagriSema failed to outperform Zepbound in a clinical trial. Zepbound, utilizing tirzepatide, is already the leading injectable obesity treatment, promising significant weight loss for patients.
Feb 23, 2026
Merck plans to establish an independent cancer division in anticipation of the impending expiration of the Keytruda patent - WKZO
Merck announced the creation of a separate division for its cancer business, centered around its leading drug Keytruda, as it prepares for the drug's patent expiry in 2028. This restructuring aims to enhance pipeline success and may allow for future business spin-offs. Analysts note the need for improved execution to counteract upcoming patent pressures.
Feb 23, 2026
Eli Lilly introduces a new version of Zepbound - Becker's Hospital Review
Eli Lilly has launched a multidose version of its weight loss drug Zepbound (tirzepatide), approved by the FDA, featuring a KwikPen that provides a month’s treatment in a single injection. Available through LillyDirect, prices start at $299 per month. tirzepatide-patent-expiration" style="color: #F36C42; font-weight:600";>Tirzepatide is also marketed as Mounjaro for Type 2 diabetes, with a similar KwikPen already offered.
Feb 23, 2026
Generic Pharmaceuticals Market Expected to Grow to USD 942.69 Billion by 2033 | - openPR.com
The Generic Drugs Market is projected to grow from USD 508.47 billion in 2024 to USD 942.69 billion by 2033, at a CAGR of 7.1%. This growth is driven by patent expirations, rising healthcare costs, and increasing demand for affordable medications. Key players include Teva Pharmaceutical Industries, Sandoz, and Amneal Pharmaceuticals, among others.
Feb 23, 2026
Merck & Co plans to separate its cancer division in anticipation of the Keytruda patent expiration - Sharecast.com
Merck & Co is spinning off its oncology operations to shield its broader healthcare business from an impending patent cliff for its blockbuster drug Keytruda. The company will create two units: one for cancer and another for non-cancer assets. This restructuring aims to enhance focus on innovative medicines as Keytruda faces competition from generics starting in 2028.
Feb 23, 2026
Merck Plans to Establish Independent Cancer Division Amid Upcoming Keytruda Patent Expiration
Merck announced the creation of a separate division for its cancer business, centered around its top-selling drug Keytruda, as it prepares for the drug's patent expiry in 2028. This restructuring aims to enhance pipeline success and may allow for future business spin-offs. Analysts caution that more work is needed to counteract upcoming patent pressures.
Feb 23, 2026
Merck establishes a distinct oncology division in anticipation of Keytruda patent expiration - TradingView
Merck announced a split of its human-health operations into two divisions to enhance focus and streamline new medicine launches. This restructuring comes as the company prepares for the loss of exclusivity for its top-selling cancer drug, Keytruda, in 2028. New leaders have been appointed, and Merck aims to leverage its expanding pipeline, including drugs like Gardasil and Ohtuvayre, for future growth.
Feb 23, 2026
Health Ministry updates regulations for testing bacterial endotoxins and pyrogens, according to DrugsControl Media Services.
The Union health ministry has amended the Drugs and Cosmetics Rules, 1945, to include bacterial endotoxins in testing requirements while excluding chemical contraceptives like centchroman and ethinyloestradiol. This change aims to enhance safety standards in pharmaceutical testing.
Feb 23, 2026
Merck plans to establish an independent cancer division in anticipation of the impending expiration of the Keytruda patent - CNBC
Merck announced a strategic split into two divisions, focusing on its cancer franchise led by Keytruda, the world's best-selling prescription drug. This move aims to diversify beyond Keytruda as key patents expire. The company has expanded its pipeline and made significant acquisitions, while also appointing Jannie Oosthuizen as president of the cancer division.
Feb 23, 2026
Eli Lilly introduces Zepbound, a pen for administering a month’s supply of its obesity medication - CNBC
Eli Lilly & Co. has launched a new multi-dose injection pen for its obesity drug, Zepbound, allowing patients to take four weekly doses from a single device, the KwikPen. Available on LillyDirect for $299 per month, this innovation aims to enhance convenience and sustain Zepbound's growing demand since its market debut in late 2023.
Feb 23, 2026
Novo Nordisk's decline erases all gains from the Wegovy period following a setback in trials | WKZO
Novo Nordisk's shares plummeted over 16% after its next-generation obesity drug, CagriSema, underperformed compared to Eli Lilly's offerings. This decline erased gains from its successful weight-loss drug, Wegovy, leading to a market value drop of around $475 billion. Eli Lilly's shares rose by 4%, highlighting increasing competition in the obesity treatment market.
Feb 23, 2026
850 Companies Under Investigation for NSQ Medications, Audit Outsourcing Set to Begin, Export Regulations Relaxed
India's drug regulator, CDSCO, is initiating a major overhaul, scrutinizing 850 firms for non-standard quality (NSQ) drugs. The plan includes outsourcing audits and easing export norms to improve drug quality and align with global standards.
Feb 23, 2026
Merck plans to establish an independent cancer division in anticipation of the impending expiration of the Keytruda patent.
Merck announced a split of its human-health business into two units, focusing on its cancer franchise led by the blockbuster drug Keytruda, which generated over US$30 billion in 2025. This restructuring aims to diversify beyond Keytruda amid concerns over future sales and competition from generics. Merck also appointed Jannie Oosthuizen as president of the cancer business.
Feb 22, 2026
By the year 2032, approximately 100 biopharmaceuticals are anticipated to have their patents expire in Europe...
A report by the Korea Biopharmaceutical Association reveals that by 2032, around 100 biopharmaceuticals will lose patents in Europe, with 79% lacking biosimilars. It urges Korean companies like Samsung Bioepis and Celltrion to focus on new treatment areas such as ophthalmology and dermatology to enhance market dominance and competitiveness. The potential cost of the biosimilar pipeline gap is estimated at $143 billion.
Feb 22, 2026
Stock valued at Rs 4 lakh seized in Vijayawada for tampering with expiry dates - drugscontrol.org
The Drugs Control Administration (DCA) in NTR District has seized medicines worth nearly Rs. 4 lakh from a pharmaceutical establishment in Vijayawada due to expiry date tampering. This action is part of intensified enforcement operations against violations of the Drugs and Cosmetics Act, 1940.
Feb 22, 2026
Formycon AG: A Discreet Biotech Investment That May Disrupt the U.S. Pharmaceutical Industry - Ad-hoc-news.de
Formycon AG, a German biotech firm, is gaining attention for its biosimilars, particularly FYB201 (a Lucentis biosimilar) and FYB202 (a Stelara biosimilar), which target the U.S. market. As biosimilars can significantly reduce drug costs, Formycon's focus on these high-revenue biologics positions it as a key player in the ongoing push for affordable healthcare solutions.
Feb 22, 2026
Roche Holding AG: Could This 'Quiet' Pharmaceutical Stock Be Your Next Strategic Investment?
Roche Holding AG is gaining attention from investors as it focuses on cancer drugs, Alzheimer’s treatments, and AI diagnostics. With a strong pipeline and a history of steady dividends, Roche faces challenges from biosimilars and US drug pricing regulations. Analysts view it as a solid, research-heavy stock, balancing growth potential with inherent biotech risks.
